Company
Mallinckrodt
- Status
- Mergedas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.
About the company
- Status notes
- On July 31, 2025, Mallinckrodt and Endo joined together to better serve patients and customers with a bold plan for the future. Following the merger, the combined company then spun off its generics and sterile injectables business as an independent company—Par Health—and rebranded the specialty therapeutics company as Keenova Therapeutics in November 2025.
Loading relationship preview